Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Black Diamond Therapeutics (BDTX)
NASDAQ:BDTX
BDTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.91 - $7.66
Previous CloseN/A
Volume170.82K
Average Volume (3M)1.09M
Market Cap
$132.41M
Enterprise Value$156.13M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.89
Next Earnings
Mar 12, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding56,585,064
10 Day Avg. Volume591,480
30 Day Avg. Volume1,091,195
Standard Deviation0.34
R-Squared0.15
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)43.23
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-357.27
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$16.00Price Target Upside575.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Black Diamond Therapeutics News
PremiumStock Analysis & Ideas
Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
Black Diamond Therapeutics Reports Promising Q3 2024 Results
PremiumCompany Announcements
Black Diamond Therapeutics Restructures to Focus on Oncology Lead Program---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBDTX-1535 elicited a 36% objective response rate in response evaluable patients, which improved to 42% after excluding patients without on-target resistance mutations.
Drug DevelopmentThe safety profile of BDTX-1535 is consistent with approved EGFR TKI class drugs, showing no severe side effects like G3/4 diarrhea or off-target effects.
EarningsBlack Diamond reported a net loss of $0.28 per share, which is narrower than the estimated net loss of $0.37 per share, due to lower-than-anticipated operating expenses.
Bears Say
Clinical UncertaintyThere is uncertainty surrounding the upcoming FDA feedback for the pivotal trial in the 2L and 3L setting for BDTX-1535.
Financial PerformanceBlack Diamond is operating at a net loss, though narrower than expected, indicating ongoing financial challenges.
RisksRisks include negative efficacy data for BDTX-1535 or BDTX-4933, and a poorer than expected efficacy or safety profile for these drugs.
---
Ownership Overview
19.47% Insiders
17.79% Mutual Funds
0.24% Other Institutional Investors
55.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BDTX FAQ
What was Black Diamond Therapeutics’s price range in the past 12 months?
Black Diamond Therapeutics lowest stock price was $1.91 and its highest was $7.66 in the past 12 months.
What is Black Diamond Therapeutics’s market cap?
Black Diamond Therapeutics’s market cap is $132.41M.
When is Black Diamond Therapeutics’s upcoming earnings report date?
Black Diamond Therapeutics’s upcoming earnings report date is Mar 12, 2025 which is in 23 days.
How were Black Diamond Therapeutics’s earnings last quarter?
Black Diamond Therapeutics released its earnings results on Nov 05, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.373 by $0.093.
Is Black Diamond Therapeutics overvalued?
According to Wall Street analysts Black Diamond Therapeutics’s price is currently Undervalued.
Does Black Diamond Therapeutics pay dividends?
Black Diamond Therapeutics does not currently pay dividends.
What is Black Diamond Therapeutics’s EPS estimate?
Black Diamond Therapeutics’s EPS estimate is -0.31.
How many shares outstanding does Black Diamond Therapeutics have?
Black Diamond Therapeutics has 56,585,064 shares outstanding.
What happened to Black Diamond Therapeutics’s price movement after its last earnings report?
Black Diamond Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.373. Following the earnings report the stock price went up 8.696%.
Which hedge fund is a major shareholder of Black Diamond Therapeutics?
Currently, no hedge funds are holding shares in BDTX
---
Black Diamond Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (575.11% Upside)
$16.00 (575.11% Upside)
Blogger Sentiment
Bullish
BDTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.23%
12-Months-Change
Fundamentals
Return on Equity
-63.09%
Trailing 12-Months
Asset Growth
-20.01%
Trailing 12-Months
Company Description
Black Diamond Therapeutics
Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
---
BDTX Stock 12 Month Forecast
Average Price Target
$16.00
▲(575.11% Upside)
Technical Analysis
Blueprint Medicines
―
Kura Oncology
―
Revolution Medicines
―
Zentalis Pharmaceuticals
―
Best Analysts Covering BDTX
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
-13.70%
assigned a buy rating 4 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -13.70% per trade.
---